Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 57

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 57
---
 ​                 | ​ | ​ | —                                                             | ​ | ​          | ​ | ​ | ​ | —                                                               | ​ |       ​ | ​ | ​ | ​ | —                      | ​ |     ​ | ​ | ​ | ​ | —                    | ​ | ​         | ​ | ​ | ​ | 37,500(7)                                             | ​ | ​        | ​ | ​ | ​ |                                               352,875 | ​ |      ​ | ​ | ​ | ​ | —                                                                                            | ​ | ​ | ​ | ​ | ​ |                                                                                                               — | ​ | ​ |   |   |
| ​                 | ​ | ​ | —                                                             | ​ | ​          | ​ | ​ | ​ | —                                                               | ​ |       ​ | ​ | ​ | ​ | —                      | ​ |     ​ | ​ | ​ | ​ | —                    | ​ | ​         | ​ | ​ | ​ | —                                                     | ​ | ​        | ​ | ​ | ​ |                                                     — | ​ |      ​ | ​ | ​ | ​ | 20,833(9)                                                                                    | ​ | ​ | ​ | ​ | ​ |                                                                                                         196,039 | ​ | ​ |   |   |

(1) Computed in accordance with SEC rules as the number of unvested RSUs multiplied by the closing market price of our ordinary shares at the end of our 2024 fiscal year, which was $9.41. The actual value (if any) to be realized by the officer depends on whether the RSUs vest and the future performance of our ordinary shares. (2) Computed in accordance with SEC rules as the number of unvested RSUs multiplied by the closing market price of our ordinary shares at the end of the 2024 fiscal year, which was $9.41. The actual value (if any) to be realized by the officer depends on whether the performance milestones related thereto are achieved, whether the award vests following achievement of the performance milestones, and the future performance of our ordinary shares. (3) Mr. Winningham was granted an annual replenishment equity award of an option under our 2013 Equity Incentive Plan on February 25, 2022. 25% of the shares subject to the option vested on February 25, 2023, and the remaining shares vest in equal monthly installments over the following three years, subject to Mr. Winningham’s continuous service through each vesting date. 36

TABLE OF